AK-FLUOR® 10% (100 mg/mL) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature.

{ "type": "p", "children": [], "text": "AK-FLUOR® 10% (100 mg/mL) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature.\n" }

Adult Dose

The recommended dosage of AK-FLUOR® 10% (100 mg/mL) is 500 mg via intravenous administration.

Pediatric Dose

For children, the dose is 7.7 mg/kg (actual body weight) up to a maximum of 500 mg, via intravenous infusion calculated on the basis of 35 mg for each 10 lbs. (4.54 kg) of body weight.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not mix or dilute with other solutions or drugs.

Inject the dose (over 5-10 seconds is normally recommended) into the antecubital vein, after taking precautions to avoid extravasation. A syringe, filled with AK-FLUOR®, may be attached to transparent tubing and a 23 gauge butterfly needle for injection. Insert the needle and draw the patient's blood to the hub of the syringe so that a small air bubble separates the patient's blood in the tubing from the fluorescein. With the room lights on, slowly inject the blood back into the vein while watching the skin over the needle tip. If the needle has extravasated, the patient's blood will be seen to bulge the skin and the injection should be stopped before any fluorescein is injected. When assured that extravasation has not occurred, the room light may be turned off and the fluorescein injection completed. Luminescence usually appears in the retina and choroidal vessels in 7 to 14 seconds and can be observed by standard viewing equipment.

Reduction in dose from 500 mg to 200 mg of AK-FLUOR® 10% may be appropriate in cases when a highly sensitive imaging system e.g., scanning laser ophthalmoscope is used.

AK-FLUOR® (fluorescein injection, USP) 10%, 500 mg/ 5mL (100 mg/ml) is a dark reddish orange, clear solution in a 5 mL single-dose vial.

{ "type": "p", "children": [], "text": "AK-FLUOR® (fluorescein injection, USP) 10%, 500 mg/ 5mL (100 mg/ml) is a dark reddish orange, clear solution in a 5 mL single-dose vial.\n" }

AK-FLUOR® is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. Rare cases of death due to anaphylaxis have been reported [see Warnings and Precautions (5.1) and Adverse Reactions (6.2)].

Caution should be exercised in patients with a history of allergy or bronchial asthma. An emergency tray should always be available.

If a potential allergy is suspected, an intradermal skin test may be performed prior to intravenous administration, i.e., 0.05 mL injected intradermally to be evaluated 30 to 60 minutes following injection. Given the sensitivity and specificity of skin testing, a negative skin test is not proof that a patient is not allergic to fluorescein.

Extravasation during injection can result in severe local tissue damage due to high pH of fluorescein solution. The following complications resulting from extravasation of fluorescein have been noted to occur: Sloughing of the skin, superficial phlebitis, subcutaneous granuloma, and toxic neuritis along the median nerve in the antecubital area. Complications resulting from extravasation can cause severe pain in the arm for up to several hours. When extravasation occurs, the injection should be discontinued and conservative measures to treat damaged tissue and to relieve pain should be implemented. [see Administration (2.3) and Adverse Reactions (6.6)].

The most common reaction is discoloration of the skin and urine. Skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours.

The next most common adverse reaction is nausea. Vomiting, and gastrointestinal distress have also occurred. A strong taste may develop after injection.

Symptoms and signs of hypersensitivity have occurred. Generalized hives and itching, bronchospasm and anaphylaxis have been reported. [see Contraindications (4.1) and Warnings and Precautions (5.1)]

Syncope and hypotension may occur. Cardiac arrest, basilar artery ischemia, severe shock and death may occur rarely. [see Warnings and Precautions (5.1)]

Headache may occur. Convulsions may rarely occur following injection.

Thrombophlebitis at the injection site has been reported. Extravasation of the solution at the injection site causes intense pain at the site and a dull aching pain in the injected arm. [see Administration (2.3) and Warnings and Precautions (5.2)].

Pregnancy Category C. Adequate animal reproduction studies have not been conducted with fluorescein sodium. It is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. Fluorescein sodium should be given to a pregnant woman only if clearly needed.

Fluorescein sodium has been demonstrated to be excreted in human milk. Caution should be exercised when fluorescein sodium is administered to a nursing woman.

Pediatric patients have been included in clinical studies. No overall differences in safety or effectiveness have been observed between pediatric and adult patients.

No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

AK-FLUOR® (fluorescein injection, USP) is a sterile solution for use intravenously as a diagnostic aid. It is a dark reddish orange solution with a pH of 8.3 to 9.8 and an osmolality of 572 to 858 mOsm/kg.

{ "type": "p", "children": [], "text": "AK-FLUOR® (fluorescein injection, USP) is a sterile solution for use intravenously as a diagnostic aid. It is a dark reddish orange solution with a pH of 8.3 to 9.8 and an osmolality of 572 to 858 mOsm/kg.\n" }

Its chemical name is spiro[isobenzofuran-1 (3H),9'-[9H]xanthene]-3-one,3'6'- dihydroxy, disodium salt.: The active ingredient is represented by the chemical structure:

{ "type": "p", "children": [], "text": "Its chemical name is spiro[isobenzofuran-1 (3H),9'-[9H]xanthene]-3-one,3'6'- dihydroxy, disodium salt.: The active ingredient is represented by the chemical structure:\n" }

MW = 376.27

{ "type": "p", "children": [], "text": "MW = 376.27\n" }

AK-FLUOR® 10% contains:

{ "type": "p", "children": [], "text": "AK-FLUOR® 10% contains:\n" }

Active: fluorescein sodium (10 % w/v, 100 mg/mL)

{ "type": "p", "children": [], "text": "Active: fluorescein sodium (10 % w/v, 100 mg/mL)\n" }

Inactives: Sodium Hydroxide and/or Hydrochloric Acid may be used to adjust pH (8.3 to 9.8), and Water for Injection.

{ "type": "p", "children": [], "text": "Inactives: Sodium Hydroxide and/or Hydrochloric Acid may be used to adjust pH (8.3 to 9.8), and Water for Injection.\n" }

Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465 to 490 nm and fluoresces, i.e., emits light at wavelengths of 520 to 530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the fluorescence of the dye demarcates the retinal and/or choroidal vasculature under observation, distinguishing it from adjacent areas/structures.

Distribution.

Within 7 to 14 seconds after IV administration into the antecubital vein, fluorescein usually appears in the central retinal artery of the eye. Within a few minutes of IV administration of fluorescein sodium, a yellowish discoloration of the skin occurs, which begins to fade 6 to 12 hours after dosing. Various estimates of volume of distribution indicate that fluorescein distributes into interstitial space (0.5 L/kg).

Metabolism.

Fluorescein is metabolized to fluorescein monoglucuronide. After IV administration of fluorescein sodium (14 mg/kg) to 7 healthy subjects, approximately 80% of fluorescein in plasma was converted to glucuronide conjugate after a period of 1 hour post dose.

Excretion.

Fluorescein and its metabolite are mainly eliminated via renal excretion. After IV administration, the urine remains slightly fluorescent for 24 to 36 hours. A renal clearance of 1.75 mL/min/kg and a hepatic clearance (due to conjugation) of 1.50 mL/min/kg have been estimated. The systemic clearance of fluorescein was essentially complete by 48 to 72 hours after administration of 500 mg fluorescein.

There have been no long-term studies done using fluorescein in animals to evaluate carcinogenic potential.

AK-FLUOR® (fluorescein injection, USP) 10%, 500 mg/5 mL (100mg/mL) is supplied in a single-dose 5 mL glass vial with a gray chlorobutyl serum siliconized stopper and orange flip-off cap. It contains a sterile dark reddish orange solution of fluorescein sodium.

{ "type": "p", "children": [], "text": "AK-FLUOR® (fluorescein injection, USP) 10%, 500 mg/5 mL (100mg/mL) is supplied in a single-dose 5 mL glass vial with a gray chlorobutyl serum siliconized stopper and orange flip-off cap. It contains a sterile dark reddish orange solution of fluorescein sodium.\n" }

(NDC 81298-8660-3) 5 mL, single dose vials in a package of 12.

{ "type": "p", "children": [], "text": "(NDC 81298-8660-3) 5 mL, single dose vials in a package of 12.\n" }

AK-FLUOR® should be stored at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Do not freeze. Discard unused portion.

{ "type": "p", "children": [], "text": "AK-FLUOR® should be stored at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Do not freeze. Discard unused portion.\n" }

After administration of fluorescein sodium, skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours. [see Warnings and Precautions (6.1)].

{ "type": "p", "children": [], "text": "After administration of fluorescein sodium, skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours. [see Warnings and Precautions (6.1)].\n" }

Rx only

{ "type": "p", "children": [], "text": "Rx only\n" }

Manufactured for: Long Grove Pharmaceuticals, LLC Rosemont, IL 60018

{ "type": "p", "children": [], "text": "Manufactured for:\nLong Grove Pharmaceuticals, LLC\nRosemont, IL 60018\n" }

Made in IndiaUS/LF/077 V02       Rev. 12/24PLF199/01

{ "type": "p", "children": [], "text": "Made in IndiaUS/LF/077 V02       Rev. 12/24PLF199/01\n" }

Principal Display Panel – 5 mL Carton Label

{ "type": "p", "children": [], "text": "\nPrincipal Display Panel – 5 mL Carton Label\n" }

NDC 81298-8660-3

{ "type": "p", "children": [], "text": "NDC 81298-8660-3\n" }

Rx Only

{ "type": "p", "children": [], "text": "Rx Only\n" }

AK-FLU0R®10%

{ "type": "p", "children": [], "text": "\nAK-FLU0R®10%\n" }

Fluorescein Injection, USP

{ "type": "p", "children": [], "text": "\nFluorescein Injection, USP\n" }

500 mg/5 mL (100 mg/mL) / 12 Sterile Vials (5mL each)

{ "type": "p", "children": [], "text": "\n500 mg/5 mL (100 mg/mL) / 12 Sterile Vials (5mL each)\n" }

LONG GROVE™ PHARMACEUTICALS

{ "type": "p", "children": [], "text": "\nLONG GROVE™\nPHARMACEUTICALS\n" }

Principal Display Panel – 5 mL Vial Label

{ "type": "p", "children": [], "text": "\nPrincipal Display Panel – 5 mL Vial Label\n" }

NDC 81298-8660-1

{ "type": "p", "children": [], "text": "NDC 81298-8660-1\n" }

Rx Only

{ "type": "p", "children": [], "text": "Rx Only\n" }

AK-FLU0R®10%

{ "type": "p", "children": [], "text": "\nAK-FLU0R®10%\n" }

Fluorescein Injection, USP

{ "type": "p", "children": [], "text": "\nFluorescein Injection, USP\n" }

500 mg/5 mL (100 mg/mL)

{ "type": "p", "children": [], "text": "\n500 mg/5 mL (100 mg/mL)\n" }

5 mL Sterile Vial

{ "type": "p", "children": [], "text": "\n5 mL Sterile Vial\n" }

For Intravenous Injection

{ "type": "p", "children": [], "text": "\nFor Intravenous Injection\n" }

FLUORESCITE® Injection 10% is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature.

{ "type": "p", "children": [], "text": "FLUORESCITE® Injection 10% is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature." }

Adult Dose- The normal adult dose of FLUORESCITE® Injection 10% (100 mg/mL) is 500 mg via intravenous administration.

For children, the dose should be calculated on the basis of 7.7 mg for each kg of actual body weight (or 35 mg for each 10 pounds of body weight) up to a maximum of 500 mg via intravenous administration.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not mix or dilute with other solutions or drugs.  Flush intravenous cannulas before and after drugs are injected to avoid physical incompatibility reactions.

Inject the dose rapidly (1 mL per second is normally recommended) intravenously into the antecubital vein, after taking precautions to avoid extravasation.  A syringe, filled with FLUORESCITE®, may be attached to transparent tubing and a 23 gauge butterfly needle for injection. Insert the needle and draw the patient’s blood to the hub of the syringe so that a small air bubble separates the patient’s blood in the tubing from the fluorescein. With the room lights on, slowly inject the blood back into the vein while watching the skin over the needle tip. If the needle has extravasated, the patient’s blood will be seen to bulge the skin and the injection should be stopped before any fluorescein is injected. When assured that extravasation has not occurred, the room light may be turned off and the fluorescein injection completed. Luminescence usually appears in the retina and choroidal vessels in 7 to 14 seconds and can be observed by standard viewing equipment.

Reduction in dose from 5 mL to 2 mL of FLUORESCITE® Injection 10% may be appropriate in cases when a highly sensitive imaging system e.g., scanning laser ophthalmoscope is used.

Single use 5 mL vial containing 100 mg/mL fluorescein.

{ "type": "p", "children": [], "text": "Single use 5 mL vial containing 100 mg/mL fluorescein. " }

FLUORESCITE® Injection 10% is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. Rare cases of death due to anaphylaxis have been reported. [see Warnings and Precautions (5.1) and Adverse Reactions (6)].

{ "type": "p", "children": [], "text": "FLUORESCITE® Injection 10% is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. Rare cases of death due to anaphylaxis have been reported. [see Warnings and Precautions (5.1) and Adverse Reactions (6)].\n" }

Fluorescein sodium can induce serious intolerance reactions. These reactions of intolerance are always unpredictable but they are more frequent in patients who have previously experienced an adverse reaction after fluorescein injection (symptoms other than nausea and vomiting) or in patients with history of allergy such as food or drug induced urticaria, asthma, eczema, allergic rhinitis.

{ "type": "p", "children": [], "text": "Fluorescein sodium can induce serious intolerance reactions. These reactions of intolerance are always unpredictable but they are more frequent in patients who have previously experienced an adverse reaction after fluorescein injection (symptoms other than nausea and vomiting) or in patients with history of allergy such as food or drug induced urticaria, asthma, eczema, allergic rhinitis." }

Detailed questioning of each patient is recommended before the angiography to evaluate any prior history of allergy.

{ "type": "p", "children": [], "text": "Detailed questioning of each patient is recommended before the angiography to evaluate any prior history of allergy." }

Caution is to be exercised in patients with a history of allergy or bronchial asthma. An emergency tray should be available in the event of possible reaction to FLUORESCITE® Injection 10%.

If a potential allergy is suspected, an intradermal skin test may be performed prior to intravenous administration, i.e., 0.05 mL injected intradermally to be evaluated 30 to 60 minutes following injection. Given the sensitivity and specificity of skin testing, a negative skin test is not proof that a patient is not allergic to fluorescein.

Care must be taken to avoid extravasation during injection as the high pH of fluorescein solution can result in severe local tissue damage.  The following complications resulting from extravasation of fluorescein have been noted to occur: severe pain in the arm for several hours, sloughing of the skin, superficial phlebitis, subcutaneous granuloma, and toxic neuritis along the median curve in the antecubital area. When significant extravasation occurs, the injection should be discontinued and conservative measures to treat damaged tissue and to relieve pain should be implemented. [see Administration (2.3) and Adverse Reactions(6)].

Nausea and/or vomiting and gastrointestinal distress occur commonly within the first few minutes following injection.  These reactions usually subside within 10 minutes.

Skin and Urine Discoloration The most common reaction is temporary yellowish discoloration of the skin and urine. Urine may attain a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours.

{ "type": "p", "children": [], "text": "\nSkin and Urine Discoloration\nThe most common reaction is temporary yellowish discoloration of the skin and urine. Urine may attain a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours. " }

Gastrointestinal Reactions Nausea, vomiting, and gastrointestinal distress are common adverse events. A strong taste may develop after injection.

{ "type": "p", "children": [], "text": "\nGastrointestinal Reactions\nNausea, vomiting, and gastrointestinal distress are common adverse events. A strong taste may develop after injection. \n" }

Hypersensitivity Reactions Symptoms and signs of hypersensitivity have occurred. Generalized hives and itching, bronchospasm and anaphylaxis have been reported.  Rare cases of death have been reported. [see Contraindications (4.1) and Warnings and Precautions (5.1)].

{ "type": "p", "children": [], "text": "\nHypersensitivity Reactions\nSymptoms and signs of hypersensitivity have occurred. Generalized hives and itching, bronchospasm and anaphylaxis have been reported.  Rare cases of death have been reported. [see Contraindications (4.1) and Warnings and Precautions (5.1)].\n\n" }

Cardiopulmonary Reactions Cardiac arrest, basilar artery ischemia, severe shock and death may occur rarely.

{ "type": "p", "children": [], "text": "\nCardiopulmonary Reactions\nCardiac arrest, basilar artery ischemia, severe shock and death may occur rarely." }

Neurologic Reactions Headache may occur. Convulsions and syncope may rarely occur following injection.

{ "type": "p", "children": [], "text": "\nNeurologic Reactions\nHeadache may occur. Convulsions and syncope may rarely occur following injection." }

Thrombophlebitis Thrombophlebitis at the injection site has been reported. Extravasation of the solution at the injection site causes intense pain at the site and a dull aching pain in the injected arm. [see Administration (2.3) and Warnings and Precautions (5.2)].

{ "type": "p", "children": [], "text": "\nThrombophlebitis\nThrombophlebitis at the injection site has been reported. Extravasation of the solution at the injection site causes intense pain at the site and a dull aching pain in the injected arm. [see Administration (2.3) and Warnings and Precautions (5.2)].\n" }

Adequate animal reproduction studies have not been conducted with fluorescein sodium.  It is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. Fluorescein sodium should be given to a pregnant woman only if clearly needed.

Fluorescein sodium injection has been demonstrated to be excreted in human milk for up to 4 days.  Following fluorescein angiography, breast-feeding should therefore be discontinued for at least 4 days and the milk should be pumped off and discarded during this period.

Pediatric patients have been included in clinical studies.  No overall differences in safety or effectiveness have been observed between pediatric and adult patients.

No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

FLUORESCITE® (fluorescein injection, USP) 10% contains fluorescein sodium (equivalent to fluorescein 10% w/v). It is a sterile solution for use intravenously as a diagnostic aid. Its chemical name is spiro[isobenzofuran-1(3H ),9'-[9H]xanthene]-3-one, 3'6'-dihydroxy, disodium salt. The active ingredient is represented by the chemical structure:

{ "type": "p", "children": [], "text": "\nFLUORESCITE® (fluorescein injection, USP) 10% contains fluorescein sodium (equivalent to fluorescein 10% w/v). It is a sterile solution for use intravenously as a diagnostic aid. Its chemical name is spiro[isobenzofuran-1(3H ),9'-[9H]xanthene]-3-one, 3'6'-dihydroxy, disodium salt. The active ingredient is represented by the chemical structure:" }

FLUORESCITE® (fluorescein injection, USP) 10% is supplied as a sterile, unpreserved, unit dose aqueous solution, that has a pH of 8.0 – 9.8 and an osmolality of 572-858 mOsm/kg.

{ "type": "p", "children": [], "text": "FLUORESCITE® (fluorescein injection, USP) 10% is supplied as a sterile, unpreserved, unit dose aqueous solution, that has a pH of 8.0 – 9.8 and an osmolality of 572-858 mOsm/kg." }

Active ingredient: fluorescein sodium

{ "type": "p", "children": [], "text": "Active ingredient: fluorescein sodium" }

Inactive Ingredients: Sodium hydroxide and/or hydrochloric acid (to adjust pH), and water for injection.

{ "type": "p", "children": [], "text": "Inactive Ingredients: Sodium hydroxide and/or hydrochloric acid (to adjust pH), and water for injection." }

Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465-490 nm and fluoresces, i.e., emits light at wavelengths of 520-530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish-green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the fluorescence of the dye demarcates the retinal and/or choroidal vasculature under observation, distinguishing it from adjacent areas/structures.

Distribution:

Within 7 to 14 seconds after intravenous (IV) administration into antecubital vein, fluorescein usually appears in the central artery of the eye. Within a few minutes of IV administration of fluorescein sodium, a yellowish discoloration of the skin occurs, which begins to fade after 6 to 12 hours of dosing. Various estimates of volume of distribution indicate that fluorescein distributes well into interstitial space (0.5 L/kg).

Metabolism:

Fluorescein undergoes rapid metabolism to fluorescein monoglucuronide.  After IV administration of fluorescein sodium (14 mg/kg) to 7 healthy subjects, approximately 80% of fluorescein in plasma was converted to glucuronide conjugate after a period of 1 hour post dose, indicating relatively rapid conjugation.

Excretion:

Fluorescein and its metabolites are mainly eliminated via renal excretion. After IV administration, the urine remains slightly fluorescent for 24 to 36 hours. A renal clearance of 1.75 mL/min/kg and a hepatic clearance (due to conjugation) of 1.50 mL/min/kg have been estimated. The systemic clearance of fluorescein was essentially complete by 48 to 72 hours after administration of 500 mg fluorescein.

There have been no long-term studies done using fluorescein in animals to evaluate carcinogenic potential.

FLUORESCITE®(fluorescein injection, USP) 10% is supplied in a single use 5 mL glass vial with a gray FluroTec coated chlorobutyl stopper and purple flip-off aluminum seal. The vial stopper is not made with natural rubber latex.  The vial contains a sterile, red-orange solution of fluorescein sodium.

NDC 0065-0092-65

Store at 2°- 25°C (36°- 77°F). Do Not Freeze

After administration of fluorescein sodium, skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours. [see Adverse Reactions (6)]

{ "type": "p", "children": [], "text": "After administration of fluorescein sodium, skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours. [see Adverse Reactions (6)]\n\n" }

Distributed By: ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA © 2006, 2016 Novartis Revised: 2/2016 9014068-0117

{ "type": "p", "children": [], "text": "\nDistributed By:\n\nALCON LABORATORIES, INC. \nFort Worth, Texas 76134 USA \n© 2006, 2016 Novartis \nRevised: 2/2016\n9014068-0117\n" }

NDC 0065-0092-65                      1 Dozen 5 mL Vials Florescite® 10% (fluorescein injection, USP) 10%STERILE100 mg/mL Fluorescein Rx Only FOR INTRAVENOUS USE Store at 2° - 25° C (36° - 77° F) Do Not Freeze Alcon® ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USA ©2000-2009 Alcon, Inc. H11427-1009 LOT: EXP.: MFD.:

{ "type": "p", "children": [], "text": "\nNDC 0065-0092-65                      1 Dozen 5 mL Vials\n\nFlorescite® 10%\n(fluorescein injection, USP) 10%STERILE100 mg/mL Fluorescein\n\nRx Only\n\nFOR INTRAVENOUS USE\nStore at 2° - 25° C (36° - 77° F)\nDo Not Freeze\n\nAlcon®\nALCON LABORATORIES, INC.Fort Worth, Texas 76134 USA\n©2000-2009 Alcon, Inc.\n\nH11427-1009\n\nLOT:\nEXP.:\nMFD.:\n" }

NDC 0065-0092-65                      1 Dozen 5 mL Vials Florescite* 10% (fluorescein injection, USP) 10%STERILE100 mg/mL Fluorescein Rx Only FOR INTRAVENOUS USE Store at 2° - 25° C (36° - 77° F) Do Not Freeze Alcon® a Novartis company Alcon Laboratories, Inc.Fort Worth, Texas 76134 USA* a trademark of Norvatis©2000, 2009, 2015 Novartis GTIN: 10300650092651 S/N: LOT: EXP.: 9010833-0615

{ "type": "p", "children": [], "text": "\nNDC 0065-0092-65                      1 Dozen 5 mL Vials\n\nFlorescite* 10%\n(fluorescein injection, USP) 10%STERILE100 mg/mL Fluorescein\n\nRx Only\n\nFOR INTRAVENOUS USE\nStore at 2° - 25° C (36° - 77° F)\nDo Not Freeze\n\nAlcon®\na Novartis company\n\nAlcon Laboratories, Inc.Fort Worth, Texas 76134 USA* a trademark of Norvatis©2000, 2009, 2015 Novartis\nGTIN: 10300650092651\nS/N:\nLOT:\nEXP.:\n9010833-0615\n" }

NDC 0065-0092-65 Fluorescite® 10% (fluorescein injection, USP) 10%100 mg/mL FLUORESCEIN 5 mL             STERILE ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USA ©2000-2009 Alcon, Inc. Rx Only H11426-0209 LOT: EXP.:

{ "type": "p", "children": [], "text": "\nNDC 0065-0092-65\n\nFluorescite® 10%\n(fluorescein injection, USP) 10%100 mg/mL FLUORESCEIN\n5 mL             STERILE\nALCON LABORATORIES, INC.Fort Worth, Texas 76134 USA\n©2000-2009 Alcon, Inc.\n\nRx Only\n\n\nH11426-0209\n\nLOT:\nEXP.:\n" }